placeholder placeholder placeholder
 

BREAKING NEWS:
MRC Technology and Biolex Therapeutics Successfully Complete Collaboration to Humanize a Novel Antibody Targeting CD20

Biolex Therapeutics Researchers Present Locteron® Phase 2a Hepatitis C Trial Results at EASL Conference
Biolex Announces Presentation of Preclinical Results for Clot Buster BLX-155 at SIR Annual Scientific Meeting
search home sitemap contacts directions disclaimer privacy
©2004 Biolex, Inc. All rights reserved.